Gary Bourgeault

About the Author Gary Bourgeault

I am a former investment advisor and owner of a number of businesses. Now I invest only for myself, while writing on a variety of business, financial and economic topics.

Cracks Are Forming in Canopy Growth (CGC) Stock

Canopy Growth (CGC) has generated more sizzle than steak over the last year or so, and I think the chinks in its armor …

Why the Next 12 Months Will Make or Break Supreme Cannabis Stock

Supreme Cannabis (SPRWF) has been under pressure lately, as it missed on revenue and earnings in its last quarter. That followed a revenue …

This Dip in Aurora Cannabis (ACB) Stock Is a Buying Opportunity

It remains puzzling to me to see the vast majority of analysts, financial writers and commentators, and the market in general, continue to …

Is the Worst Over for Namaste Technologies (NXTTF) Stock?

Namaste Technologies (NXTTF) has endured a lot of self-inflicted pain in the past months, as scandals, firings, loss of an auditor, and a …

A Look at Amazon (AMZN) Stock and Rising Expectations

It seems nothing can slow Amazon (AMZN) down, as the company continues to hit it out of the park, and a growing number …

Competition Concerns Derail on Trulieve Cannabis Stock

For some time Trulieve (TCNNF) has enjoyed a significant market lead in the Florida cannabis market, having built up a solid retail and …

Cannabis Stock Hexo Can Go a Bit Higher Here, but Caution Is Warranted

HEXO (HEXO) has been getting a lot of attention lately, primarily based upon what is considered a fairly low valuation, leading market share …

Does Marijuana Stock OrganiGram (OGI) Rely Too Much on Recreational Cannabis?

OrganiGram Holdings (OGI) has a strong position in the Canadian recreational pot market, recently receiving a supply deal with Quebec, making it only …

Love or Hate Aurora Cannabis (ACB) Stock, That’s Where the Money Is

Aurora Cannabis (ACB) is a stock that is usually either loved or hated. It took me a while to figure out what all …

Medicinal Cannabis Stock GW Pharmaceuticals (GWPH) Could Run Much Higher Over Time

GW Pharmaceuticals (GWPH) has recently bounced after a solid earnings report. It also announced its phase-3 trial concerning its Epidiolex oral medicine, received …

Stay Ahead of Everyone Else

Get The Latest Stock News Alerts